Drug Shortage Active
DURAMORPH PF is currently in shortage. Reason: Unavailable. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
DURAMORPH PF (morphine sulfate) by Hikma is mu-opioid receptor, although it can bind to other opioid receptors at higher doses. Approved for pain, chronic pain, postoperative pain and 1 more indications. First approved in 1984.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
DURAMORPH PF is a parenteral formulation of morphine sulfate, a full mu-opioid receptor agonist indicated for acute and chronic pain management including postoperative and cancer pain. It works by binding to opioid receptors in the central nervous system to produce analgesia without a ceiling effect on pain relief.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team rationalization and shift toward defensive positioning.
mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of morphine is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with morphine. Clinically, dosage is titrated to provide adequate analgesia and may…
Worked on DURAMORPH PF at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo
Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR)
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moEmployment linked to DURAMORPH PF is limited (0 identified open positions) and focused on defensive commercial and operational roles rather than growth or innovation. Career progression on this product is constrained by its LOE-approaching lifecycle stage, current supply shortage, and lack of competitive differentiation or pipeline activity.